7TM Pharma
Copenhagen, Denmark
7TM Pharma is a privately held biotech company focusing on discovery and development of new drugs targeting 7TM receptors. 7TM Pharma’s primary therapeutic area is metabolic diseases, including obesity, diabetes and cardiovascular diseases. 7TM’s lead compound, Obinepitide, targets the treatment of obesity and is in Phase II clinical studies. A second obesity compound entered Phase I/II studies in early 2006.
Ablynx NV
Ghent, Belgium
Ablynx is a biopharmaceutical company working on a novel class of therapeutics, called Nanobodies®. Nanobodies® are single domain antibodies that appear to have the affinity and selectivity of traditional antibodies but are much smaller in size. This latter property potentially gives Nanobodies® several advantages over regular antibodies. The Company has a rich and diverse pipeline. Ablynx is a public company trading on NYSE-Euronext Brussels (ticker: ABLX).
AcelRx Pharmaceuticals, Inc.
Portola Valley, California
AcelRx Pharmaceuticals is an early stage company developing a novel drug delivery platform technology.
Contact: Guy P. Nohra
Achaogen, Inc.
South San Francisco, California,
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections.
Contact: Farah Champsi
Aegerion Pharmaceuticals, Inc.
Bridgewater, NJ
Aegerion Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of pharmaceutical products to treat cardiovascular and metabolic diseases.
Aerie Pharmaceuticals, Inc.
Research Triangle Park, NC
Aerie Pharmaceuticals is a privately held, clinical-stage biotechnology company dedicated to the discovery and development of novel treatments for glaucoma. Aerie’s internal research and development engine has generated an innovative glaucoma pipeline. In addition to AR-12286, the Company’s Rho-kinase (ROCK) inhibitor, the pipeline includes AR-13165, a novel product candidate with a dual mechanism of action that represents the first of a new proprietary class of glaucoma drugs. AR-13165 is currently in preclinical, IND-enabling studies. An ocular implant for long-term drug delivery is also being advanced towards the clinic. The Company is located in Bridgewater New Jersey and Research Triangle Park North Carolina
Aerovance, Inc.
Berkeley, CA
Aerovance is a privately held biopharmaceutical company exclusively focused on the development and commercialization of biologics for respiratory and inflammatory diseases. The Company’s lead products are Aerovant™, an IL4/13 receptor antagonist for severe asthma and eczema that is currently in Phase II clinical studies, and Aeroderm, a novel therapeutic for eczema.
Contact: Farah Champsi
Alba Therapeutics Corp.
Baltimore, MD
Alba Therapeutics is focused on the development of novel therapeutics for the treatment of inflammatory and immune mediated diseases caused by the malfunction of tight junctions in body. Initial target diseases are Celiac Disease and Type I Diabetes. The Company is in Phase II studies.
Contact: Dan Janney
San Mateo, CA
Allakos is a privately held, product-focused biotechnology company developing first-in-class antibody-based therapeutics to treat diseases in which dysregulation of the Th2 response plays a key role in pathology, including allergic disease, inflammation and diseases characterized by excess production of inflammatory cells. Allakos has generated a preclinical pipeline of novel antibodies targeting cell types implicated in allergic and inflammatory responses which it intends to advance to clinical proof-of-concept. Headquartered in the San Francisco Bay Area, Allakos is led by a management team with broad experience in antibody research and development and a strong advisory board of experts in the areas of disease focus.
Applied Genetic Technologies Corporation
Alachua, FL
Applied Genetic Technologies Corporation is a gene therapy company focused on curing genetic defects that cause blindness and other systemic disorders. The Company is developing a pipeline of products that utilize its proprietary, adeno-associated virus (AAV) delivery system and herpes-helper virus production technology.
Astex Pharmaceuticals, Inc.
Cambridge, England
Astex Pharmaceuticals™ is a leader in innovative drug discovery, development and commercialization, committed to the fight against cancer and other life-threatening diseases.
Contact: Dan Janney
aTyr Pharma, Inc.
San Diego, CA
aTyr Pharma is a privately held biopharmaceutical company focused on identifying and developing a novel class of naturally occurring protein biologics for human therapeutics.
Azelon Pharmaceuticals, Inc.
West Conshohocken, PA
Azelon Pharmaceuticals, formerly Zelos Therapeutics, is developing a novel parathyroid hormone (PTH) analogue called Ostabolin-C™ for the treatment of osteoporosis which has completed Phase II trials. The Company has other Ostabolin-C™ programs in clinical development.
Contact: Farah Champsi
Cara Therapeutics, Inc.
Tarrytown, NY
Cara Therapeutics is a private, clinical stage company developing novel, first in class treatments for pain and inflammatory disorders. The Company’s most advanced programs are in the field of kappa opiate receptor agonists and cannabanoid receptor agonists and antagonists.
Ceregene, Inc.
San Diego, CA
Using gene therapy delivery systems, Ceregene’s primary focus is the discovery and development of novel growth factor therapeutics for the treatment of neurological disorders. Ceregene has completed Phase I clinical trials in Alzheimer’s and Parkinson’s disease, and is currently conducting a double blind Phase II trial in Parkinson’s disease.
Cerenis Therapeutics
Toulouse, France and Ann Arbor, MI
Cerenis Therapeutics is a pharmaceutical company focused on the discovery, development and commercialization of HDL-related therapies for the treatment of cardiovascular and metabolic diseases. Based on breakthrough research in HDL therapy, Cerenis is pursuing a range of HDL product candidates that reflect significant commercial opportunities in the treatment of atherosclerosis. The two lead programs are around a synthetic HDL mimetic and a PPAR delta agonist.
ChemoCentryx, Inc.
MountainView, CA
ChemoCentryx is a focused pharmaceutical company engaged in drug discovery and development of first-in-class small molecule medicines targeting the chemokine system for autoimmune diseases, inflammatory disorders and oncology. ChemoCentryx’s most advanced clinical candidate, Traficet®, a CCR9 antagonist, is in Phase II studies for GI inflammatory indications.
Contact: Ed Penhoet, Ph.D.
Chimerix Inc.
Durham, North Carolina
Chimerix is a privately held drug development company which owns proprietary lipid prodrug technology to improve the efficacy of antiviral drugs. The Company’s lead compound, CMX001, is an active agent against a number of DNA viruses including smallpox and papilloma. Chimerix is also developing programs in CMV and HIV and is pursuing commercial opportunities to broaden the use of its technology.
Contact: Farah Champsi
Corcept Therapeutics, Inc.
Menlo Park, CA
Corcept Therapeutics is developing therapeutics for the treatment of severe psychiatric and neurological diseases. Specifically, Corcept is focused on the clinical development of a pharmaceutical compound, CORLUX, for the treatment of psychotic major depression (PMD). Nasdaq: CORT
Cymabay Therapeutics
Hayward, CA
CymaBay Therapeutics (formerly Metabolex, Inc.) is a clinical-stage biopharmaceutical company developing breakthrough therapies addressing unmet medical needs. Arhalofenate, the Company’s lead product candidate, possesses two therapeutic actions in a single drug. In gout patients, Arhalofenate is intended to prevent painful attacks in joints while at the same time promoting excretion of uric acid by the kidney, thereby removing the root cause of this debilitating disease. Arhalofenate’s differentiated profile is intended for use in a large population, with significant advantages over marketed and emerging agents which have limitations in their efficacy, tolerability, and use in patients with common comorbidities. CymaBay also has two additional clinical stage product candidates with the potential to be targeted towards high unmet need specialty and orphan diseases.
Contact: Ed Penhoet, Ph.D.
Cytokinetics, Inc.
South San Francisco, CA
Cytokinetics is developing novel pharmaceuticals and technologies based on its expertise in cytoskeletal pharmacology and biology. The Company is currently pursuing multiple therapeutic programs in the areas of cancer and cardiovascular diseases. It is in Phase II studies with small molecule therapeutics for solid tumors and for congestive heart failure.
Nasdaq: CYTK
Contact: Farah Champsi
DiscoveRx Corp.
Fremont, CA
DiscoveRx® develops, manufactures, and commercializes reagents and complete assay kits for the drug discovery and screening markets. The Company’s products, biochemical and cell-based assays enable customers to improve research productivity and effectiveness, thus accelerating the discovery and development of new drugs.
Contact: Dan Janney
Esperion Therapeutics (spin-out)
Plymouth, MI
Esperion Therapeutics, Inc. discovers and develops therapies to prevent, treat, and reverse cardiovascular and metabolic diseases.
Contact: Dan Janney
Excaliard Pharmaceuticals
Encinitas, California
Excaliard is a private biotechnology company focused on the development and commercialization of antisense drugs for the local treatment of scarring and other fibrotic diseases.
Contact: Farah Champsi
Genedata AG
Basel, Switzerland
GeneData develops and commercializes bioinformatics systems and related services in the functional genomics arena. The Company delivers computational solutions for the management and analysis of large quantities of structurally complex biological data, generated by genome sequencing, microarrays, protein expression profiling, metabolic profiling and high-throughput screening.
Immune Design Corp.
Seattle, Washington
Immune Design is a clinical-stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. The Company’s technologies are engineered to activate the immune system’s natural ability to create and/or expand antigen-specific cytotoxic T cells, while enhancing other immune effectors, to fight cancer and other chronic diseases. Immune Design's clinical programs are the product of its two synergistic discovery platforms: ZVexTM and GLAASTM. Immune Design went public in July 2014 and is listed on NASDAQ under the symbol IMDZ.
Contact: Ed Penhoet, Ph.D.
Intarcia Therapeutics, Inc.
Hayward, CA
Intarcia Therapeutics, Inc. is a privately held biopharmaceutical company developing therapies to ensure enhanced treatment outcome by optimizing patient adherence and improving the efficacy, convenience and tolerability of drug therapies. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above body temperature and to deliver them in a constant and consistent manner via the proprietary DUROS drug delivery platform. Intarcia is pursuing a clinical stage development program for type 2 diabetes and has other programs for weight regulation to control obesity. The Company’s headquarters and manufacturing facilities are in Hayward, CA.
Kiadis Pharma
Amsterdam, The Netherlands
Kiadis is a private Dutch biopharmaceutical company. Its product pipeline is focused on overcoming limitations and complications of bone marrow transplantation (BMT) procedures for the treatment of end-stage blood cancer patients. The most advanced program, ATIR, is in Phase III multinational registration trial.
Kite Pharma, Inc.
Los Angeles, California
Kite Pharma, Inc. is a privately held development stage biotechnology company engaged in the development of novel cancer immunotherapeutic products with focus on engineered autologous T cell therapy (eACT), designed at restoring the patient's immune system to recognize and eradicate tumors. In partnership with the National Cancer Institute (NCI) Surgery Branch, Kite is advancing a pipeline of proprietary eACT product candidates directed to a wide range of cancer indications. These novel personalized and targeted immunotherapies, which capitalize on the selectivity and potency of immune cells, are aimed at providing significant and durable clinical benefit regardless of tumor origin, disease stage, and prior treatments. In addition, the company is advancing a novel therapeutic cancer vaccine aimed to trigger potent and specific immunity against multiple epithelial cancers, which has the potential to complement its eACT programs.
Contact: Farah Champsi
Lumena Pharmaceuticals
San Diego, CA
Lumena Pharmaceuticals is a privately-held biotechnology company developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically impact patient health. The company’s clinical-stage product candidates carry a reduced risk of systemic toxicities by selectively targeting a transporter in the intestine and are designed to be minimally absorbed in the body. Lumena’s lead candidate, LUM001, has been extensively evaluated in other indications across 12 clinical studies in more than 1,400 subjects. Because of the extensive preclinical and clinical data package, LUM001 is positioned to rapidly progress through the clinic in pediatric and adult patients with several types of cholestatic liver disease.
MacroGenics, Inc.
Rockville, MD
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms, which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. The company creates both differentiated molecules that are directed to novel cancer targets, as well as "bio-betters," which are drugs designed to improve upon marketed medicines. The combination of MacroGenics' technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.
San Diego, California,
Lithera is a privately held clinical stage developer of pharmaceutical and biomedical products addressing both medical and lifestyle indications in ophthalmology and aesthetic medicine. Lithera’s lead product candidate (LIPO-102) is a novel, injectable pharmaceutical treatment designed to produce local, selective fat tissue reduction (pharmaceutical lipoplasty).
Contact: Dan Janney
Nereus Pharmaceuticals, Inc.
San Diego, CA
Nereus Pharmaceuticals is a pioneer in the use of marine microbial sources for the discovery and follow-on development of new therapeutics for cancer and inflammatory and infectious diseases. The Company’s two oncology drug candidates are in Phase I clinical trials. NPI-2358, a tumor vascular disrupting agent, is being evaluated for solid tumors, and a proteasome inhibitor, NPI-0052, is being developed for solid tumors, lymphomas and multiple myeloma.
Pathwork Diagnostics
Redwood City, CA
Pathwork Diagnostics Inc. is a privately held company that develops and delivers innovative molecular diagnostics for oncology. Pathwork's Tissue of Origin Test identifies the source of cancers that are difficult to classify and increases oncologists’ confidence in their treatment approaches. It is the only FDA-approved molecular diagnostic test for tissue of origin.
Portola Pharmaceuticals, Inc.
South San Francisco, CA
Portola Pharmaceuticals is dedicated to the discovery and development of innovative small molecule therapeutics for the prevention and treatment of thrombosis and cardiovascular disease. The Company is in Phase II trials with a Factor Xa inhibitor and an ADP receptor antagonist.
Contact: Farah Champsi
Proacta Therapeutics
San Diego, CA
Proacta Therapeutics is developing a new generation of cancer drugs that uniquely target physiological attributes of solid tumors. Proacta’s first lead program, a hypoxia targeted small-molecule prodrug, is designed to improve the outcomes of current treatment regimens, including chemotherapy and radio-therapy. Proacta is currently conducting a Phase II trial in small cell lung cancer.
Prolacta Bioscience
Monrovia, CA
Prolacta BioScience is a life science company dedicated to the application of science relating to human milk. Prolacta is the pioneer in human milk-based nutritional products for critically-ill and premature infants in the Neonatal Intensive Care Unit. It has created the first and only commercially available Human Milk Fortifier made from 100% human milk, Prolact-Plus™.
Contact: Dan Janney
San Francisco, CA
SARcode is a venture-backed biopharmaceutical company focused on the development of best in class small molecule LFA-1 antagonists as novel nonsteroidal immunomodulators/anti-inflammatory agents for the treatment of Tcell mediated inflammatory diseases. The Company’s lead program, targeting dry eye disease, is preparing to enter Phase III trials.
Scynexis, Inc.
Research Triangle Park, NC
SCYNEXIS is a privately held drug discovery and development company that provides a full range of synthetic chemistry processes and technology to the life sciences industry. In addition to providing development services industry, the Company is also developing a proprietary internal pipeline based on cyclophilin inhibitors, a class of drugs that hold significant potential for a broad range of diseases. The Company has a corporate partnership with Merck to discover and develop anti-fungal and antibacterial anti-infective compounds, as well as an animal health partnership with Merial (a joint venture between Merck and Sanofi-Aventis).
Contact: Ed Penhoet, Ph.D.
Silence Therapeutics
London, England
Silence Therapeutics possesses multiple RNAi discovery, development and delivery technologies, a broad internal and partnered product pipeline and a broad portfolio of intellectual property.
Sonexa Therapeutics, Inc.
San Diego, California
Sonexa Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of Alzheimer's disease.
Sunesis Pharmaceuticals, Inc.
South San Francisco, CA
Sunesis Pharmaceuticals is a public clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. The Company’s most advanced compound, SNS595, has shown promising activity in multiple tumor types including refractory ovarian carcinoma and relapsed/refractory AML.
Nasdaq: SNSS
Sutro Biopharma
Menlo Park, California
Sutro Biopharma is creating opportunities for the development of novel protein-based therapeutics and vaccines using a proprietary cell-free protein synthesis technology. Cell-free technology has the potential to overcome many of the significant limitations associated with using whole mammalian and bacterial cells for making protein-based biologics.
Threshold Pharmaceuticals, Inc.
Redwood City, CA
Threshold Pharmaceuticals is a public biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of cancer. The Company is developing cancer agents that will take advantage of the lack of oxygen in tumors (hypoxia).
Nasdaq: THLD
Trevena, Inc.
King of Prussia, Pennsylvania
The biased ligand company. Trevena is a privately held biotechnology company focused on discovery and development of the next generation of GPCR targeted medicines. By designing molecules biased towards specific signaling pathways, Trevena aims to unlock new biology and avoid drug side effects. Trevena’s primary therapeutic areas are cardiovascular, pain and inflammation. TRV120027, the lead program in the Trevena portfolio, is an AT1R beta-arrestin biased ligand in Phase 2a studies for acute heart failure.
Contact: Farah Champsi
Copenhagen, Denmark
Veloxis (formerly LifeCycle Pharma) has developed a clinically validated drug-delivery platform for overcoming the deficiencies of drugs with low water-solubility, thus improving the bioavailability of marketed drugs and new chemical entities (NCEs). The Company’s clinical pipeline currently focuses on cardiovascular disease and immunosuppression. LCP has a diversified pipeline, including a product ready for US commercialization, five product candidates in clinical trials and three in preclinical stages of development.
Copenhagen Exchange: LCP.CO
ViroBay, Inc.
Menlo Park, California
ViroBay is a biotechnology company focused on developing novel HCV protease and polymerase inhibitors.
Contact: Dan Janney
Hertogenbosch, Netherlands
VitrOmics (formerly PamGene) develops valuable knowledge and tools in the field of Predictive Genomics. The necessary research are carried out by using in vitro exposure systems based on human cells and applying the latest genomics technologies.
Cambridge, MA
Zafgen is developing first in class drugs to treat obesity and related co-morbidities. The Company’s lead program, Beloranib is in Phase II clinical trials.
ZS Pharma, Inc.
Coppell, TX
ZS Pharma is a late-stage company developing a drug to treat Hyperkalemia. Hyperkalemia is a serious and potentially life-threating condition where one’s potassium levels become dangerously elevated causing arrhythmias and cardiac arrest. Hyperkalemia is most often seen in patients with chronic kidney disease (CKD) due to renal insufficiency and the condition is exacerbated by medications that these patients typically take (i.e. they increase serum potassium). In the U.S. alone there are approximately 25 million people with CKD and this number is expected to increase for the foreseeable future.
Contact: Guy P. Nohra